



Industry
Meets
Academia

PRAGUE 2015



IMI CEE CONFERENCE

30th April 2015, 9:00 a.m. – 4:00 p.m.

“ *Would you like to work with prestigious pharmaceutical industry teams on international, cutting-edge biomedical research projects?* ”

REGISTRATION



Conference Outline

The conference programme is designed and intended primarily for scientists, researchers and technology transfer professionals.

- **Ongoing IMI Consortia**
Introduction of running projects both from industry and academia perspective.
- **Practicalities**
Cooperation between industry and academia.
- **Stakeholders roundtable discussion hosted by the Czech Parliament**
CEE authorities with EFPIA and IMI JU representatives (side meeting held at the Czech Senate premises).
- **Workshops**



Conference Programme

9:00

Opening

Opening remarks

Josef VYMAZAL, Deputy Minister of Health of the Czech Republic

PPP in biopharmaceutical industry

Richard BERGSTRÖM, Director General, EFPIA

IMI JU efforts

IMI JU representative

Czech Academia

Tomas ZIMA, Rector of the Charles University in Prague

9:45

Main Programme

9:45

Ongoing IMI Consortia [part 1]

AETIONOMY:

The need to develop a new taxonomy of human disease

Duncan MCHALE, UCB

Towards a mechanism-based taxonomy of neurodegenerative diseases:
overview on the AETIONOMY project

Martin HOFMANN-APITIUS, Fraunhofer SCAI

ELF (European Lead Factory):

A pharma perspective onto the European Lead Factory

Stefan JAROCH, Bayer HealthCare & Ton RIJNDERS, TI Pharma

10:45

Coffee Break

11:15

11:15

Ongoing IMI Consortia [part 2]

EMIF (European Medical Information Framework):

Public-private partnership consortium aiming at efficient and safe reuse of patient-level data

Bart VANNIEUWENHUYSE,
Janssen

EBiSC (European Bank for induced pluripotent stem cells):

The industry challenges and the public sector response

Timothy ALLSOPP, Pfizer & Aidan COURTNEY, Roslin Cells

12:15

10:30

Stakeholders Discussion

We warmly welcome all top representatives of the appropriate national authorities and institutions, such as Ministry of Health, Ministry of Education or Ministry of Science etc., to join the discussion with the representatives of European Federation of Pharmaceutical Industries and Associations (EFPIA) and Innovative Medicines Initiative Joint Undertaking (IMI JU), and help us identify key challenges the biomedical sector will face in the forthcoming years. We aim to create a platform tackling the policy making issues as well as novel approaches in support for biomedical research efforts on both national and European levels.

Side Programme

12:30

Main Programme

12:15

Practicalities

Technology Transfer Best Practices:
Unlocking the Potential of Academic-Industrial Partnerships
Stefanie POSSEKEL, Ascenion

Intellectual Property: Assessment of Research Results by Industry Players
to be confirmed

13:15

Best Practice: Successful technology transfer from the CEE
to be confirmed

13:15

Lunch

14:00

14:15

Split-out Workshops

Six separate workshops with the key-note speakers

16:00

[REGISTRATION](#)

[Event Website](#)




Venue

National Library of Technology (Main program)
Technická 6/2710, Prague 6

Institute of Organic Chemistry and Biochemistry (for the selected split up sessions)
Flemingovo nám. 2, Prague 6

Senate of the Parliament of the Czech Republic (Roundtable discussion)

Valdštejnské náměstí 17/4, Praha 1



Speakers



Bart Vannieuwenhuys, MSc., MBA/MBI **Senior Director Health Information Sciences** **Janssen R&D**

In 1985, Bart joined Janssen Pharmaceutica as a clinical trial monitor. In the course of his career with Janssen, Bart has held a variety of marketing and sales positions, both at local operating company level (e.g. the Netherlands) and at international level. While in Netherlands he was one of the pioneers that started “Healthy Solutions”, a J&J daughter company that focused on developing integrated services in the healthcare field. Later, he was in the core team that developed the initial CRM approach for Janssen EMEA. Between 1999 and 2003, Bart spent 4 years in the IM department of

Janssen Pharmaceutica in the US, where he was responsible for the e-business initiatives and for the overall IM technical architecture. Bart joined the EMEA CRM Center of Excellence in April 2003, where he prepared the CRM Roadmap for the short to mid-term. In 2009 Bart was instrumental in developing a new customer-orientation project for Janssen Europe. In 2011 Bart joined the Janssen R&D group to focus on external eHealth / Health Information projects with external partners. Currently, Bart is coordinator of the IMI funded EMIF (European Medical Information Framework) project.



Prof. Duncan McHale
Vicepresident, Head of Global Exploratory Development
UCB

Duncan has spent 15 years in industry focusing on pharmacogenetics, early development and personalised medicine, and holds a PhD in genetics. He joined UCB in 2011 as the Head of Global Exploratory Development. This group is responsible for the early testing of new therapies in humans in collaboration with the New Medicines Therapeutic area colleagues. Prior to joining UCB Duncan was the head of Translational Sciences at AstraZeneca and established the Clinical Personalised Healthcare and Biomarkers group there. The key prod-

uct the group worked on was Iressa, which was AstraZeneca's first Personalised Medicine. Prior to AstraZeneca Duncan was the European head of Translational and Molecular Medicine at Pfizer and led the biomarker strategy for Maraviroc, which is Pfizer's first anti HIV drug. He was also the chair of the EFPIA Pharmacogenetics working party and was one of the authors of the ICH E15 and E16 guidelines focusing on biomarker development and qualification. Currently is Duncan also the Industry coordinator and leader for the Taxonomy of Human disease within IMI's project AETIONOMY.



Prof. Dr. Martin Hofmann-Apitius
Head of Department for Bioinformatics
Fraunhofer Institute for Algorithms and Scientific Computing
SCAI

Martin Hofmann-Apitius holds a PhD in Molecular Biology and worked for more than 10 years in experimental molecular biology. The screening for novel genes involved in tumour metastasis lead him into the area of functional genomics and subsequently to applied bioinformatics. Martin Hofmann-Apitius has experience in both, academic (University of Heidelberg (ZMBH), Forschungszentrum Karlsruhe (ITG), German Cancer Research Center(DKFZ))and industrial(BASF,Boehringer Ingelheim, LION bioscience AG) research.

Since 2002 he is leading the Department of Bioinformatics at the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) in Sankt Augustin (Germany), a governmental non-profit research institute. In July 2006 he has been appointed a Professor for Applied Life Science Informatics at Bonn-Aachen International Center for Information Technology (B-IT). Martin Hofmann-Apitius is (co-) author of more than 130 scientific publications. Martin Hofmann-Apitius is initiator and academic coordinator of IMI project AETIONOMY (www.aetionomy.org).



Dr. Stefanie Possekel
Director Technology Management
Ascenion

Stefanie spent more than 10 years in the pharmaceutical and biotech industry and has broad experience in in- and outlicensing of clinical and preclinical projects and setting up academic-industrial partnerships. In October 2012, Stefanie Possekel joined Ascenion, an IP asset management company focused on the life sciences in Munich. Before, she served as Director Strategic Alliances with global responsibilities for the Musculoskeletal Disease Area

and Oncology at Novartis. Prior to that she worked as Director Business Development at Santhera Pharmaceuticals, a Swiss-based specialty pharmaceutical company. Stefanie studied Biology at the Philipps University Marburg, Germany with a specific focus on Microbiology, Immunology, Genetics and Biochemistry and received her PhD in 1995. During her thesis she spent time at the Biocenter in Basel and worked closely with researchers at the Institute of Myology in Paris, France.



Timothy Allsopp, PhD.
Co-ordinator IMI project EBiSC
Neusentis (a Pfizer research unit)

Tim is a biology graduate from University of London & has published in the field of stem cells, regenerative medicine (Reading JL et al, J. Immunol. 2013; Hook L et al Neurochem Int. 2011; Allsopp T et al Med. Chem. Comm 2010). He has 14 years industrial experience in the translation of stem cell science, the development of regenerative cell therapies and product development. Before joining Pfizer he was CSO of a stem cell biotech company. He is considered a subject matter specialist in stem cells, reviewing

and evaluating technology for internationally funded, public sector and charity supported regenerative medicine programmes. He is co-chair of the ISSCR Industry Committee, and Director on the ISSCR Board, an industry representative, advisory group member for the Commercialization Committee of the ISCT. He teaches and mentors students and tenure track investigators in a number of academic programmes & holds a Programme Associate position at the Cambridge university MBE course in biotechnology.



Stefan Jaroch, PhD.
Head External Innovation Technologies
Global External Innovation & Alliances
Bayer HealthCare

Stefan Jaroch studied chemistry at the University of Bonn and obtained his PhD from the Ludwig Maximilians-Universität, Munich, in 1993. After a postdoc at the University of California, Irvine, he joined Schering AG and worked as medicinal chemist from 1995-2000 in Berlin and from 2000-2001 at the US subsidiary Berlex Biosciences in Richmond, CA. From 2001-2007, he was director in the medicinal chemistry department in Berlin, and from 2007-2010 in the medicinal chemistry department of Bayer Schering Pharma in Wuppertal. In his 15 years of pharma research experi-

ence his main interests were in the areas of anti-inflammation and oncology research. He holds an honorary professorship at the chemistry department of the Philipps-Universität Marburg since 2008. Since 2010, he focuses on collaborations with partners from academia, research institutes, pharmas, biotechs, and CROs. As Head of External Innovation Technologies he is responsible for partnering activities referring to early drug discovery assets, technologies, and services, also including open innovation approaches. As of April 2015 he also acts as Project Coordinator in IMI's European Lead Factory.



Ton Rijnders, PhD.
Scientific Director
TI Pharma

Ton Rijnders holds a PhD in molecular biology. He joined Organon in 1986 and became Vice President Research in 2003. After the acquisition of Organon by Schering-Plough in 2007, Ton was appointed VP Discovery and Site Head Oss within the Schering-Plough Research Institute. After the merger of Merck with Schering-Plough Ton continued to head Discovery in Oss within the

Merck Research Labs until 2011. He was one of the founding fathers of TI Pharma, a public private partnership in drug discovery which manages a portfolio of over 50 consortia with a total investment of around € 300m. In 2011 Ton has taken up responsibility as Scientific Director at TI Pharma. In addition, from 2013 onwards Ton is also Head of the European Screening Centre, part of the IMI European Lead Factory.



Organizers



Association of Innovative Pharmaceutical Industry (AIFP)



European Federation of Pharmaceutical Industries and Associations (EFPIA)



Auspices



Ministry of Health of the Czech Republic



Senate, Parliament of the Czech Republic



POSLANECKÁ SNĚMOVNA
PARLAMENTU ČESKÉ REPUBLIKY

Chamber of Deputies, Parliament of the Czech Republic



UNIVERZITA KARLOVA

Charles University in Prague



Event's Partners



Innovative Medicines Initiative

Innovative Medicines Initiative Joint Undertaking (IMI JU)



Association of Innovative Pharmaceutical Manufacturers (AIPM)



Union of Innovative Pharmaceutical Companies (INFARMA)



Slovak Association of Innovative Pharmaceutical Industry (AIFP)



Asociatia Romana a Producatorilor Internazionali de Medicamente (ARPIM)



The Association of the manufacturers of innovative drugs (INOVIA)



The Association of Pharmaceutical Manufacturers in Estonia (APME)



Innovative Pharmaceutical Initiative (IFI)



The Innovative Pharmaceutical Industry Association (IFPA)



MedChemBio Czech Republic



Technology Agency of the Czech Republic



Institute of Organic Chemistry and Biochemistry AS Czech Republic



Forum of International Research and Development Pharmaceutical Companies (EIG) - TBC



Association of International Research-based Pharmaceutical Manufacturers (SIFFA) - TBC